Cel-Sci Corporation (CVM): Price and Financial Metrics


Cel-Sci Corporation (CVM): $11.49

0.16 (+1.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

CVM POWR Grades


  • Value is the dimension where CVM ranks best; there it ranks ahead of 42.14% of US stocks.
  • CVM's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • CVM's current lowest rank is in the Stability metric (where it is better than 3.3% of US stocks).

CVM Stock Summary

  • With a price/sales ratio of 17,117.92, Cel Sci Corp has a higher such ratio than 99.79% of stocks in our set.
  • Revenue growth over the past 12 months for Cel Sci Corp comes in at -95.69%, a number that bests merely 1.04% of the US stocks we're tracking.
  • The volatility of Cel Sci Corp's share price is greater than that of 94.24% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CVM, based on their financial statements, market capitalization, and price volatility, are ZOM, MRSN, TFFP, INMB, and MVIS.
  • CVM's SEC filings can be seen here. And to visit Cel Sci Corp's official web site, go to cel-sci.com.

CVM Valuation Summary

  • CVM's price/sales ratio is 17182.8; this is 151290.31% higher than that of the median Healthcare stock.
  • Over the past 203 months, CVM's price/sales ratio has gone up 17050.5.
  • Over the past 203 months, CVM's price/sales ratio has gone up 17050.5.

Below are key valuation metrics over time for CVM.

Stock Date P/S P/B P/E EV/EBIT
CVM 2021-08-31 17182.8 8.3 -14.6 -14.5
CVM 2021-08-30 16141.4 7.8 -13.7 -13.5
CVM 2021-08-27 16010.3 7.8 -13.6 -13.4
CVM 2021-08-26 15103.4 7.3 -12.9 -12.6
CVM 2021-08-25 15237.9 7.4 -13.0 -12.7
CVM 2021-08-24 14865.5 7.2 -12.7 -12.4

CVM Growth Metrics

  • Its year over year revenue growth rate is now at -61.88%.
  • The 3 year revenue growth rate now stands at 63.25%.
  • Its year over year cash and equivalents growth rate is now at -49.36%.
Over the past 30 months, CVM's revenue has gone down $549,300.

The table below shows CVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.02858 -17.57112 -34.0548
2021-03-31 0.226299 -16.07044 -35.12843
2020-12-31 0.543473 -15.00238 -32.93686
2020-09-30 0.597427 -15.27616 -30.27698
2020-06-30 0.663927 -15.57706 -29.57738
2020-06-30 0.663927 -15.57706 -29.57738

CVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CVM has a Quality Grade of D, ranking ahead of 8.38% of graded US stocks.
  • CVM's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • LJPC, LFVN, and DVAX are the stocks whose asset turnover ratios are most correlated with CVM.

The table below shows CVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -0.804
2021-03-31 0.005 1 -0.962
2020-12-31 0.013 1 -1.050
2020-09-30 0.016 1 -0.998
2020-06-30 0.020 1 -1.012
2020-06-30 0.020 1 -1.012

CVM Stock Price Chart Interactive Chart >

Price chart for CVM

CVM Price/Volume Stats

Current price $11.49 52-week high $40.91
Prev. close $11.33 52-week low $7.08
Day low $11.24 Volume 295,932
Day high $11.93 Avg. volume 1,273,498
50-day MA $10.85 Dividend yield N/A
200-day MA $15.77 Market Cap 494.39M

Cel-Sci Corporation (CVM) Company Bio


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.


CVM Latest News Stream


Event/Time News Detail
Loading, please wait...

CVM Latest Social Stream


Loading social stream, please wait...

View Full CVM Social Stream

Latest CVM News From Around the Web

Below are the latest news stories about Cel Sci Corp that investors may wish to consider to help them evaluate CVM as an investment opportunity.

CVR Medical Corp. Announces Completion of 2021 2nd Quarter Financial Statement

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - CVR Medical Corp. (TSXV: CVM) (OTC Pink: CRRVF) ("CVR Medical" or the "Company" or "we"), a Canadian listed and US-based healthcar

FinanzNachrichten | August 31, 2021

CVM: Primum Non Nocere

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Third Quarter Fiscal Year 2021 Operational and Financial Results CEL-SCI Corporation (NYSE: CVM ) announced third

Business Insider Markets | August 29, 2021

CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results

VIENNA, Va., August 16, 2021--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.

Yahoo | August 16, 2021

T Cell Surface Glycoprotein CD4 Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Biotest AG, Bristol-Myers Squibb Co, CEL-SCI Corp, Fountain Biopharma Inc, Immup

This report studies the T Cell Surface Glycoprotein CD4 Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the T Cell Surface Glycoprotein CD4 []

Jumbo News | July 22, 2021

CVM: Data Has Been Released

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Data Readout From the IT MATTERS Trial On June 28, 2021, CEL-SCI Corporation (NYSE:CVM) reported selected data from the IT-MATTERS trial. While details for the primary endpoint were not provided, an important subset of the population in the Multikine arm produced a statistically significant 14.1% improvement in overall survival

Yahoo | July 8, 2021

Read More 'CVM' Stories Here

CVM Price Returns

1-mo -2.13%
3-mo 49.61%
6-mo -52.95%
1-year -10.16%
3-year 252.45%
5-year 91.50%
YTD -1.46%
2020 27.43%
2019 218.82%
2018 51.85%
2017 8.00%
2016 -81.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9213 seconds.